ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended September 30,2012.

K. Raghavendra Rao has submitted to the Exchange vide letter dated October 26, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K. Raghavendra Rao has submitted to the Exchange vide letter dated October 17, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the proceeding of the Annual General Meeting of the Company held on September 20, 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the results of the postal ballot.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the details of voting resutls of Annual General Meeting held on September 20, 2012 in terms of Clause 35A of the Listing Areement .

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of Voting through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, for seeking their consent for the sale and transfer of Company's Penem and Penicillins API business and the NPNC API facility located at Aurangabad together with the associated R&D infrastructure at Shozhanganallur, Chennai to Hospira Healthcare India Private Limited.

K. Raghavendra Rao has submitted to the Exchange vide letter dated August 30, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a media release dated August 29, 2012, titled "Orchid Pharma enters into agreement to transfer its Penicillin & Penem API business & its API facilities in Aurangabad to Hospira for approximately US$ 200 million".

Bhoomijha Murali has submitted to the Exchange vide letter dated August 23, 2012 a copy of disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 14, 2012, titled "Orchid pharma registers a turnover of Rs 407 crore in Q1 FY13".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

K. Raghavendra Rao has submitted to the Exchange vide letter dated July 30, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Adurjee & Bros. Private Limited has submitted to the Exchange vide letter dated July 23, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

K. Raghavendra Rao has submitted to the Exchange vide letter dated July 16, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 .

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri. T. A. Ganesh and instead appointed Shri. K. Biju George, Deputy General Manager, IDBI Bank Ltd, Chennai as its nominee on the Board of the Company with effect from June 06, 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Allotment Committee of the Board of Directors has allotted 10,000 equity shares of Rs.10 each upon exercise of vested options by one of the employees under ESOP-2010 scheme on May 17, 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2012, titled "Orchid Pharma registers 6% growth in FY12".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 14, 2012 has recommended a dividend of Rs. 3/- per share on the equity share of Rs.10/- each. Further, the dividend on Equity shares, will be paid subject to the approval of shareholders in the ensuing Annual General Meeting, and the same will be paid / dispatched during 2nd week of August 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 02, 2012, titled "Orchid Pharma receives US FDA approval for Naratriptan Tabs ANDA".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 25, 2012, titled "Orchid Pharma receives US FDA approval for Olanzapine Tabs ANDA".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Hon'ble High Court of Madras has sanctioned the Scheme of Amalgamation for Merger of Orchid Research Laboratories Limited with Orchid Chemicals & Pharmaceuticals Limited.

R. Vijayalakshmi has submitted to the Exchange vide its letter dated March 01, 2012 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 .

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 28, 2012, titled "Orchid redeems Foreign Currency Convertible Bonds (FCCBs) due in February 2012".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 08, 2012 titled "Orchid Pharma's strong growth trajectory continues in Q3 FY12".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2011 as follows: Net Sales of Rs. 46380.79 lacs for quarter ending on 31-DEC-2011 against Rs. 42714.76 lacs for the quarter ending on 31-DEC-2010. Net Profit / (Loss) of Rs. (1012.47) lacs for the quarter ending on 31-DEC-2011 against Rs. 5256.61 lacs for the quarter ending on 31-DEC-2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 02, 2012, titled "Orchid Pharma receives US FDA approval for Levofloxacin Tabs ANDA".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri R. Sankaran has resigned from the Board of the Company with effect from January 09, 2012.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on January 07, 2012, inter-alia has approved a Scheme of Amalgamation ('the Scheme') for merger of company's wholly owned subsidiary viz. Orchid Research Laboratories Limited ('the transferor company') with Orchid under the provisions of Sections 391 to 394 of the Companies Act, 1956. The Appointed date of the Amalgamation is April 01, 2010 and the Scheme is subject to the approval of The Hon'ble High Court of Madras. The transferor company being a wholly owned

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 02, 2012, titled "Orchid Pharma reports successful completion of Phase-I study of its novel PDE4 inhibitor molecule, OCID 2987"

R. Vijayalakshmi has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange a copy of disclosure under Regulation 13(3) and (6) of the Securities and Exchange Board of India (Prohibhition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 20, 2011, titled "Orchid's drug discovery research initiative with Merck advances Anti-infective program meets preclinical milestone".

R. Vijayalakshmi has submitted to the Exchange a copy of Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 and Disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 19, 2011, titled "Orchid Pharma ties up funds for FCCB redemption".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Proceedings of the Postal Ballot process of the Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the shareholders of the Company by way of postal ballot have approved on December 08, 2011, with requisite majority, the repricing of 8,64,500 options granted to employees on October 28, 2010 under Orchid ESOP 2010 Scheme, from Rs.329.55 to Rs.166.15 per share.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange vide its letter dated December 08, 2011 regarding Result of Postal Ballot.

R. Vijayalakshmi has submitted to the Exchange a copy of Disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Compensation Committee of the Board at its meeting held on November 01, 2011, has approved the following : (1) The issue of 42,700 stock options to the employees of the Company under Orchid ESOP - Senior Management 2011 Scheme. The said stock options are to be issued at par and are convertible into equity shares of Rs. 10/- each; (2) The issue of 3,00,000 stock options to the Directors of the Company under Orchid ESOP - Directors 2011 Scheme. These options are convertible into equity shares of Rs. 10/- each at a pric

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 01, 2011, titled "Orchid Pharma registers strong performance in Q2/H1 FY12; Net profit of Rs. 23 crore in Q2 FY12".

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 41222.25 lacs for quarter ending on 30-SEP-2011 against Rs. 36832.34 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 2343.2 lacs for the quarter ending on 30-SEP-2011 against Rs. 2401.49 lacs for the quarter ending on 30-SEP-2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that there was a fire that broke out in a portion of the New Drug Discovery Laboratories located in the Company's research subsidiary Orchid Research Laboratories Limited, Sholinganallur, Chennai. The fire was brought under control by the Tamil Nadu Fire Services squad assisted by the Orchid safety team. There was damage to office and laboratory equipment, furniture and building interiors. However, there were no injuries to anyone.

Orchid Chemicals & Pharmaceuticals Limited the Exchange a copy of disclosure under Regulation 13(3) and (6) of the Securities and Exchange Board of India (Prohibhition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on July 29, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 16, 2011, titled "Orchid resumes production in its API plant in Chennai".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Dr. M. R. Girinath and Dr. I. Seetharam Naidu, who were Directors on the Board of Orchid were due to retire by rotation at the Annual General Meeting held on July 29, 2011. Both the directors retired from their directorship with effect from the close of the AGM, as they opted not to get re-elected.